We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00946673
First Posted: July 27, 2009
Last Update Posted: October 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Griffith R Harsh, Stanford University
July 23, 2009
July 27, 2009
October 6, 2017
June 2009
July 2014   (Final data collection date for primary outcome measure)
  • The maximum tolerated dose of vorinostat with concurrent radiosurgery will be determined. [ Time Frame: 30 days following Stereotactic Radiosurgery ]
  • During the expanded phase I portion of the study, the safety of the Maximum tolerated dose dose will be confirmed. [ Time Frame: 30 days following Stereotactic Radiosurgery ]
  • The radiologic response, defined as local control and distant intra-cranial control rates at 3-months following radiotherapy, will be determined. [ Time Frame: 3 months following Stereotactic Radiosurgery ]
  • The safety of the MTD of vorinostat concurrent with radiotherapy will be confirmed.
  • The radiologic response, defined as local control and distant intra-cranial control rates at 3-months following radiotherapy, will be determined.
  • The MTD and DLT of daily vorinostat concurrent with SRS will be determined.
Complete list of historical versions of study NCT00946673 on ClinicalTrials.gov Archive Site
  • The short-term (< 30 days post-treatment) and long-term (> 30 days post-treatment) adverse effects will be determined. [ Time Frame: 12 months ]
  • The 12-month survival rate from the date of Stereotactic Radiosurgery will be determined. [ Time Frame: 12 months ]
  • The short-term (< 30 days post-treatment) and long-term (> 30 days post-treatment) adverse effects will be determined.
  • The 12-month survival rate from the date of SRS will be determined.
Not Provided
Not Provided
 
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Brain Cancer
  • Neoplasm Metastasis
  • Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Drug: Vorinostat
    Orally up to 400 mg
  • Procedure: Radiation Therapy
    Single fraction stereotactic radiotherapy - Standard of Care
Experimental: vorinostat & stereotactic radiosurgery
Interventions:
  • Drug: Vorinostat
  • Procedure: Radiation Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
July 2015
July 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation.
  • Adequate organ function (section 3.1.10).
  • ECOG performance status 0-2.
  • Life expectancy of >=12 weeks.
  • Systemic chemotherapy washout period >=7 days.

Exclusion Criteria:

Patients who have previously been treated with whole brain irradiation, pediatric patients (age <18), pregnant women, and patients who are unable to give informed consent.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00946673
LUN0036
Not Provided
Not Provided
Not Provided
Griffith R Harsh, Stanford University
Stanford University
National Comprehensive Cancer Network
Principal Investigator: Griffith R. Harsh Stanford University
Stanford University
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP